Heart failure with preserved ejection fraction represents a highly complex syndrome that challenges clinicians across the globe. Recent clinical investigations have explored the therapeutic utility of dapagliflozin in HFpEF to reduce adverse cardiovascular events. However, the precise cellular and hemodynamic mechanisms through which sodium-glucose cotransporter-2 inhibitors exert their beneficial effects remain an area of intense research.

Pathophysiological Heterogeneity and Dapagliflozin in HFpEF

Heart failure with preserved ejection fraction involves marked diastolic left ventricular stiffness. This stiffening typically stems from two interrelated pathological processes. First, extensive myocardial extracellular matrix remodeling drives interstitial collagen deposition. Second, titin-based cardiomyocyte hyperphosphorylation and oxidative stress impair intrinsic myocyte elasticity. Preclinical models showed that sodium-glucose cotransporter-2 inhibitors effectively reduce cardiomyocyte resting tension. Furthermore, experimental research demonstrated that these agents diminish systemic inflammation and coronary microvascular dysfunction. Consequently, researchers hypothesized that dapagliflozin could directly improve left ventricular distensibility before irreversible structural fibrosis develops. In particular, clinicians frequently encounter individuals during this early, highly pliable stage of disease. In this specific cohort, intrinsic cardiomyocyte stiffness predominates over irreversible collagen accumulation. Therefore, selectively targeting active myocyte compliance provides an attractive therapeutic strategy. In addition, clarifying these cellular dynamics helps clinicians differentiate distinct disease stages. Ultimately, determining whether pharmacological therapy improves ventricular distensibility establishes realistic expectations for clinical management.

Trial Design and Multi-Level Phenotypic Stratification

The STADIA-HFpEF trial evaluated this pathophysiological hypothesis through an innovative methodology. Investigators conducted a 34-week, randomized, double-blind, placebo-controlled crossover study. Specifically, the protocol randomized thirty-two carefully stratified patients between February 2020 and October 2022. Importantly, twenty-nine participants completed both treatment periods. The study population featured a median age of 73 years and included 28 women. To isolate cardiomyocyte-driven stiffness, investigators implemented rigorous phenotypic stratification. For example, they utilized comprehensive cardiac magnetic resonance imaging to exclude overt structural cardiomyopathies. In addition, imaging verified the absence of significant myocardial extracellular matrix expansion. Each participant received dapagliflozin 10 mg daily or matching placebo for 13 weeks. Subsequently, an 8-week washout period separated the two treatment blocks. This crossover design minimized inter-individual variability across hemodynamic and biochemical measurements. As a result, the investigators isolated the pharmacological effects of dapagliflozin with substantial statistical power.

Primary Hemodynamic Outcomes and Diastolic Stiffness

To evaluate diastolic mechanics, the investigators selected two co-primary endpoints. These endpoints were the ratio of E/e' to left ventricular end-diastolic volume index and mean left ventricular e'. Together, these echocardiographic indices reliably reflect left ventricular distensibility and active relaxation. Notably, the trial yielded completely neutral primary results. Dapagliflozin did not significantly alter the distensibility ratio compared with placebo. Specifically, the ratio shifted from 0.24 to 0.26 during active therapy, versus 0.23 to 0.25 with placebo. This finding produced a non-significant p-value of 0.370. Similarly, dapagliflozin failed to enhance left ventricular relaxation. Mean e' measured 6.2 at baseline and remained 6.2 after dapagliflozin therapy. In comparison, placebo values transitioned from 6.6 to 6.7, generating a non-significant p-value of 0.448. Moreover, most key secondary endpoints exhibited neutral patterns between treatment phases. For instance, six-minute walk distance and standardized health-related quality of life questionnaires showed no clear differences. Consequently, short-term treatment did not overcome established intrinsic ventricular compliance barriers.

Exploratory Findings in Left Atrial Strain and Inflammation

Although primary left ventricular parameters remained unchanged, the trial revealed intriguing exploratory signals. In particular, investigators recorded an isolated improvement in left atrial conduit strain during dapagliflozin administration. Left atrial conduit function reflects reservoir compliance and atrioventricular coupling during early ventricular filling. Therefore, this positive alteration suggests potential benefits on left atrial mechanical dynamics. In addition, dapagliflozin produced numerical reductions in circulating inflammatory biomarkers. Systemic microvascular inflammation represents a fundamental driver of endothelial impairment and diastolic dysfunction. Hence, dampening inflammatory cascades may explain some clinical advantages observed in broad population studies. However, clinicians must interpret these findings with appropriate prudence. Because the STADIA-HFpEF trial possessed a modest sample size, these secondary observations remain strictly hypothesis-generating. Furthermore, isolated improvements in atrial parameters do not establish comprehensive hemodynamic remodeling. Accordingly, larger prospective randomized trials must validate whether atrial conduit improvements translate into fewer clinical decompensations.

Clinical Implications for Modern Heart Failure Practice

These rigorous findings provide valuable context for managing heart failure across clinical practice. Landmark cardiovascular outcome trials previously proved that SGLT2 inhibitors lower hospitalizations and cardiovascular mortality. Nevertheless, the STADIA-HFpEF study demonstrates that dapagliflozin does not directly alter resting diastolic stiffness over thirteen weeks. Instead, the profound clinical benefits observed in large trials likely arise through alternative physiological mechanisms. For example, SGLT2 inhibitors stimulate sustained osmotic diuresis and promote systemic natriuresis. These actions effectively diminish central plasma volume and lower ventricular preload. Furthermore, these agents improve renal function, optimize systemic arterial compliance, and enhance cellular energetics. Consequently, clinicians should not withhold SGLT2 inhibitors simply because resting echocardiographic diastolic indices remain stable. Instead, physicians should continue prescribing guideline-directed medical therapy to achieve comprehensive systemic protection. Ultimately, addressing multi-organ pathways represents the most effective strategy to improve long-term functional status and survival in this vulnerable population.

Reconciling Mechanistic Trials With Outcome Evidence

Bridging the gap between physiological studies and clinical practice requires careful pathophysiological understanding. While small trials delineate precise organ-level mechanics, large-scale outcome trials capture holistic systemic benefits. Specifically, heart failure with preserved ejection fraction is not merely a cardiac disorder. Rather, it represents a multifaceted systemic syndrome involving adiposity, renal impairment, and microvascular rarefaction. SGLT2 inhibitors alter systemic metabolic pathways by shifting myocardial fuel utilization toward efficient ketone oxidation. In addition, these drugs reduce epicardial adipose tissue volume and blunt pro-fibrotic signaling over prolonged treatment horizons. Therefore, thirteen weeks may simply represent too brief an exposure to reverse complex intrinsic cardiomyocyte stiffness. Moreover, resting echocardiographic parameters cannot fully reflect hemodynamic improvements during physical exertion. For instance, dapagliflozin might significantly attenuate exertional pulmonary capillary wedge pressure spikes without modifying baseline distensibility. Thus, clinicians should integrate both mechanistic discoveries and robust clinical trial data when delivering comprehensive cardiovascular care.

Why did dapagliflozin fail to improve left ventricular distensibility in the STADIA-HFpEF trial?

The STADIA-HFpEF trial showed that thirteen weeks of dapagliflozin therapy did not significantly improve left ventricular distensibility or relaxation. Although experimental models suggested direct cellular effects on titin phosphorylation, short-term therapy may not suffice to alter intrinsic myocyte stiffness in elderly clinical cohorts. Furthermore, resting echocardiographic indices like E/e' over end-diastolic volume may lack the sensitivity needed to capture subtle resting microvascular changes in early disease stages.

How do these results align with large outcome trials like DELIVER?

Large landmark trials like DELIVER firmly proved that dapagliflozin reduces cardiovascular mortality and worsening heart failure events. However, these clinical benefits do not depend entirely on reversing intrinsic diastolic stiffness. Instead, dapagliflozin acts through potent systemic mechanisms, including sustained natriuresis, plasma volume optimization, afterload reduction, and improved renal hemodynamics. Therefore, clinicians can confidently prescribe dapagliflozin for prognostic benefit despite neutral changes on resting left ventricular distensibility measurements.

What clinical significance should doctors attach to the improved left atrial strain?

In the STADIA-HFpEF trial, dapagliflozin produced an isolated improvement in left atrial conduit strain and modest biomarker reductions. Left atrial conduit function reflects compliance and ventricular filling pressures. Consequently, improved atrial mechanics could help protect against elevated filling pressures during dynamic stress. However, because this trial evaluated a small cohort, this secondary finding remains strictly hypothesis-generating and requires confirmation in dedicated, adequately powered prospective imaging studies.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. It is not intended to diagnose, treat, cure, or prevent any condition. Always seek the advice of a qualified healthcare provider regarding medical conditions or treatments. Reliance on any information is at your own risk. Refer to the latest local and national guidelines for clinical practice.

References

1. Scheffer M et al. Dapagliflozin in phenotypically stratified HFpEF without myocardial fibrosis: the STADIA-HFpEF randomized crossover trial. Eur Heart J Cardiovasc Pharmacother. 2026 Oct 17. doi: undefined. PMID: 42888932.
2. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098.
3. Scheffer M, Driessen-Waaijer A, Hamdani N, et al. Stratified treatment of heart failure with preserved ejection fraction: rationale and design of the STADIA-HFpEF trial. ESC Heart Fail. 2020;7(6):4478-4487.
4. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-3317.